Product
Nafamostat
Aliases
Futhan, Nafamostat Mesylate
6 clinical trials
10 indications
Indication
pharmacokineticsIndication
SepsisIndication
Sepsis-Induced CoagulopathyIndication
Nafamostat MesilateIndication
Renal failureIndication
BleedingIndication
COVID-19Indication
Critical IllnessIndication
Anticoagulant therapyClinical trial
A Single Dose Study to Evaluate the Pharmacokinetics of Oxycodone and PF614 When PF614 Solution is Co-Administered With Nafamostat, as an Immediate Release Solution and/or Extended Release (ER) Capsule Formulations in Healthy SubjectsStatus: Completed, Estimated PCD: 2023-04-26
Clinical trial
Use of Nafamostat Mesilate for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation After Cardiac Surgery: Efficacy and SafetyStatus: Not yet recruiting, Estimated PCD: 2026-03-01
Clinical trial
Nafamostat Mesilate in the Treatment of Severe Infection-associated Coagulopathy: a Multicenter Randomized Controlled TrialStatus: Not yet recruiting, Estimated PCD: 2026-10-01
Clinical trial
The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Diathesis Undergoing Hemodialysis: A Pilot StudyStatus: , Estimated PCD: 2023-12-31
Clinical trial
RAndomized Clinical Trial in COvid19 Patients to Assess the Efficacy of the Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor NAfamostat (RACONA Study)Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Efficacy and Safety of Nafamostat Mesylate for VV-ECMO Anticoagulation: a Randomized, Single-blind, Multicenter Exploratory, Heparin-controlled TrialStatus: Recruiting, Estimated PCD: 2024-10-01